Benzinga··Vandana SinghAstraZeneca Splits on HPP Drug as COPD Candidate Advances
AstraZeneca's efzimfotase alfa succeeds in pediatric HPP trials but fails in adults. Meanwhile, tozorakimab meets COPD endpoints across smoker populations.
AZNPhase 3 trialsCOPD